ArticleScientific reports2025
Dehydrotanshinone II A alleviates osteoarthritis via activating PPARγ to inhibit ferroptosis in chondrocytes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated Transcriptomics and Machine Learning Reveal Lipid Metabolism Related Genes in Ischemic Stroke.Journal of molecular neuroscience : MN · 2026Article
- Secoisolariciresinol diglucoside alleviates inflammatory injury in osteoarthritis chondrocytes through ERBB2-associated JAK2/STAT3 signaling: network pharmacology and experimental validation.Frontiers in immunology · 2026Article
- Osteoarthritis: multitissue pathology, molecular mechanisms, clinical management, and emerging precision and regenerative therapies.Frontiers in pharmacology · 2025Review
- Glutathione peroxidase 4 as an emerging therapeutic target in osteoarthritis: focus on ferroptosis.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Osteoarthritis (OA) is a prevalent chronic degenerative joint disease. Ferroptosis, an iron-dependent form of programmed cell death, has been implicated as a crucial contributor to OA progression. Simiao Powder, a classical traditional Chinese medicine formula, has been widely used in clinical practice to treat inflammatory diseases such as gout and OA. However, its regulatory effects on ferroptosis remain unclear. This study investigates whether Simiao Powder could alleviate OA by regulating ferroptosis and analyzes its underlying mechanisms. We integrated multiple bioinformatics analyses along with in vivo and in vitro experiments to elucidate the mechanism by which DHT IIA treats OA. Potential therapeutic targets of Simiao Powder were identified through the TCMSP and GEO databases, and their potential biological functions were evaluated using GO enrichment, ROC curve analysis, molecular docking, and immune infiltration assessment via CIBERSORTx. OA was induced in SD rats using a high carbohydrate and fat diet, followed by a 16-week intervention with DHT IIA. Histological staining, OARSI scoring, and cartilage thickness measurements were performed. The expression levels of PPARγ, GPX4, and the apoptosis marker TUNEL in rat cartilage were evaluated using immunofluorescence and immunohistochemistry. In an LPS-induced ATDC5 chondrocyte injury model, Western blotting was used to assess the expression of PPARγ, COL2A1, ACSL4, and MMP13. Furthermore, the scTenifoldKnk algorithm was applied to perform a virtual knockout of PPARγ based on the GSE216651 single-cell RNA-seq dataset to explore its downstream regulatory effects. Bioinformatics analysis identified five key genes (CDKN1A, HMOX1, DPP4, GJA1, and PPARγ), among which PPARγ and HMOX1 exhibited strong predictive potential with AUC values > 0.8. Molecular docking analysis revealed that DHT IIA exhibited the lowest binding energy with PPARγ (-8.15 kcal/mol), indicating it as the most likely therapeutic target. In vitro and in vivo experiments demonstrated that DHT IIA significantly upregulated PPARγ expression reduced ACSL4, MMP13 and TUNEL levels, increased COL2A1 and GPX4 expression levels. Meanwhile computer simulated gene knockdown also laterally confirmed that PPARγ is a key gene affecting ferroptosis and OA development. The study confirmed that DHT IIA could improve the articular cartilage structure of OA rats by elevating PPARγ and inhibiting ferroptosis. This study reveals that DHT IIA, the active ingredient of Simiao Powder, may alleviate OA by inhibiting ferroptosis through the activation of PPARγ. These findings provide a new molecular mechanism basis for the treatment of OA by Simiao Powder, as well as scientific support for the subsequent drug development and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.